<DOC>
	<DOCNO>NCT02013349</DOCNO>
	<brief_summary>To evaluate long-term safety performance DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System</brief_summary>
	<brief_title>DESolve Post-Approval Study</brief_title>
	<detailed_description>DESolve currently approve sale United States .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient must least 18 year age Patient able verbally confirm understand risk , benefit treatment alternative receive DESolve NE BCSS he/she provide write informed consent , approve appropriate Ethics Committee respective clinical site , prior clinical study related procedure Patient must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study electrocardiogram ( ECG ) change consistent ischemia ) Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery Patient must agree undergo clinical study require followup visit Patient must agree participate clinical study period two year follow index procedure Angiographic Inclusion Criteria Target Lesion/Vessel Target lesion must locate native coronary artery nominal vessel diameter 2.75 3.5 mm assess visual estimation QCA Target lesion must measure ≤ 24 mm length Target lesion must major artery branch visually estimate stenosis ≥ 50 % &lt; 90 % TIMI flow ≥ 1 Percutaneous intervention lesion target vessel : Not part clinical investigation ≥ 6 month prior study index procedure ≥ 9 month study index procedure ( plan ) Previous intervention distal &gt; 10 mm target lesion Patient know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure CK CKMB return within normal limit time procedure Patient currently experience clinical symptom consistent AMI Patient require use rotablator intervention index procedure Patient current unstable arrhythmias Patient known leave ventricular ejection fraction ( LVEF ) &lt; 30 % Patient receive heart transplant organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy malignancy within 30 day prior procedure Patient receive immunosuppression therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus ) Patient receive chronic anticoagulation therapy ( e.g. , heparin , Coumadin ) stop restart accord local hospital standard procedures Patient know hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , Novolimus , PLLA polymer contrast sensitivity adequately premedicated Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease Patient know renal insufficiency ( e.g. , serum creatinine level 2.5 mg/dL , patient dialysis ) Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebrovascular accident ( CVA ) transient ischemic neurological attack ( TIA ) within past six month Patient significant GI urinary bleed within past six month Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance clinical study plan , confound data interpretation associate limited life expectancy ( i.e. , less one year ) Patient already participate another clinical study Women childbearing potential undergone surgical sterilization postmenopausal ( define amenorrheic least one year ) well woman pregnant nursing Patient unable give consent , legally incompetent , institutionalized virtue order issue court authority Angiographic Exclusion Criteria Target Lesion/Vessel Target lesion ( ) meet follow criterion : Aortoostial location Left main location Located within 5 mm origin LAD LCX Located within arterial saphenous vein graft distal diseased arterial saphenous vein graft Lesion involve side branch &gt; 2mm diameter bifurcation Previous placement scaffold proximal within 10 mm target lesion Total occlusion ( TIMI flow 0 ) , subtotal occlusion ( TIMI flow 1 ) Excessive tortuosity proximal within lesion Angulation ( ≥ 45o ) proximal within lesion Calcification moderate heavy Previous intervention restenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>